Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune …
Z Long, W Xiang, W Xiao, Y Min, F Qu… - Frontiers in …, 2024 - frontiersin.org
Artemisinin and its derivatives are widely recognized as first-line treatments for malaria
worldwide. Recent studies have demonstrated that artemisinin-based antimalarial drugs …
worldwide. Recent studies have demonstrated that artemisinin-based antimalarial drugs …
Neuraminidase 1 regulates neuropathogenesis by governing the cellular state of microglia via modulation of Trem2 sialylation
LE Fremuth, H Hu, D van de Vlekkert, I Annunziata… - Cell Reports, 2025 - cell.com
Summary Neuraminidase 1 (NEU1) cleaves terminal sialic acids from sialoglycoproteins in
endolysosomes and at the plasma membrane. As such, NEU1 regulates immune cells …
endolysosomes and at the plasma membrane. As such, NEU1 regulates immune cells …
[HTML][HTML] CHI3L1 in Multiple Sclerosis—From Bench to Clinic
I Jatczak-Pawlik, A Jurewicz, M Domowicz… - Cells, 2024 - pmc.ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system
(CNS) with a complex and not fully understood etiopathological background involving …
(CNS) with a complex and not fully understood etiopathological background involving …
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis
L Höpner, U Proschmann, H Inojosa… - Frontiers in …, 2024 - frontiersin.org
Background The primary treatment for acute relapses in multiple sclerosis (MS) is the
intravenous administration of high-dose methylprednisolone (IVMP). However, the …
intravenous administration of high-dose methylprednisolone (IVMP). However, the …
[HTML][HTML] A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective
T Guerra, P Iaffaldano - International Journal of Molecular Sciences, 2025 - mdpi.com
In multiple sclerosis (MS), there is significant evidence indicating that both progression
independent of relapse activity (PIRA) and relapse-related worsening events contribute to …
independent of relapse activity (PIRA) and relapse-related worsening events contribute to …
[HTML][HTML] Loss of Cells in the Retinal Ganglion Cell Layer as an Early Indication of Neurodegeneration in Multiple Sclerosis
N Shenoy, F Liu, SP Narayanan - Journal of Integrative Neuroscience, 2024 - imrpress.com
Background: Multiple Sclerosis (MS) is a debilitating neurological disease affecting the
central nervous system and significantly impacting patients' quality of life. MS is known as an …
central nervous system and significantly impacting patients' quality of life. MS is known as an …
Neuraminidase 1 regulates the cellular state of microglia by modulating the sialylation of Trem2
LE Fremuth, H Hu, D van de Vlekkert, I Annunziata… - bioRxiv, 2024 - biorxiv.org
Neuraminidase 1 (NEU1) cleaves terminal sialic acids from sialoglycoproteins in
endolysosomes and at the plasma membrane. As such, NEU1 regulates immune cells …
endolysosomes and at the plasma membrane. As such, NEU1 regulates immune cells …
Anàlisi del dany de la via visual i la seva associació amb la discapacitat en les malalties inflamatòries desmielinitzants del sistema nerviós central
S Alba Arbalat - 2024 - diposit.ub.edu
[cat] INTRODUCCIÓ: L'esclerosi múltiple (EM), l'espectre de la neuromielitis òptica
(NMOSD) i la malaltia associada als anticossos contra la glicoproteïna de la mielina …
(NMOSD) i la malaltia associada als anticossos contra la glicoproteïna de la mielina …